The Advisory Committee of the US Food and Drug Administration met on December 10 to discuss the Covid19 vaccine from Pfizer and its partner BioNTech. This committee voted and approved the urgent use licensing recommendation for the vaccine in the United States.
With 17 positive, 4 against and 1 abstentions, the Advisory Committee of the US Food and Drug Administration (FDA) recommended emergency licensing for the Covid-19 vaccine from Pfizer and BioNTech. This committee approved the safety and efficacy of the vaccine for separate age groups 16 and older.
FDA will rely on the committee’s recommendation to make a final decision, which is expected to be on December 11 (US time). If the vaccine is approved by the FDA, the millions of doses of the vaccine are expected to immediately begin being distributed to states across the US. The Trump administration’s rapid vaccine development campaign says there are plans to ship the vaccine 24 hours after the vaccine is approved.